Systemic therapies for intrahepatic cholangiocarcinoma.
Antineoplastic Agents
/ therapeutic use
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Bile Duct Neoplasms
/ drug therapy
Chemotherapy, Adjuvant
/ methods
Cholangiocarcinoma
/ drug therapy
Humans
Immune Checkpoint Inhibitors
/ therapeutic use
Immunotherapy
/ methods
Incidence
Molecular Targeted Therapy
/ methods
Treatment Outcome
Tumor Microenvironment
/ genetics
Adjuvant therapy
Checkpoint inhibitors
FGFR
IDH
Journal
Journal of hepatology
ISSN: 1600-0641
Titre abrégé: J Hepatol
Pays: Netherlands
ID NLM: 8503886
Informations de publication
Date de publication:
02 2020
02 2020
Historique:
received:
05
09
2019
revised:
08
10
2019
accepted:
09
10
2019
entrez:
20
1
2020
pubmed:
20
1
2020
medline:
8
7
2021
Statut:
ppublish
Résumé
Intrahepatic cholangiocarcinoma (iCCA) is a highly lethal hepatobiliary neoplasm whose incidence is increasing. Largely neglected for decades as a rare malignancy and frequently misdiagnosed as carcinoma of unknown primary, considerable clinical and investigative attention has recently been focused on iCCA worldwide. The established standard of care includes first-line (gemcitabine and cisplatin), second-line (FOLFOX) and adjuvant (capecitabine) systemic chemotherapy. Compared to hepatocellular carcinoma, iCCA is genetically distinct with several targetable genetic aberrations identified to date. Indeed, FGFR2 and NTRK fusions, and IDH1 and BRAF targetable mutations have been comprehensively characterised and clinical data is emerging on targeting these oncogenic drivers pharmacologically. Also, the role of immunotherapy has been examined and is an area of intense investigation. Herein, in a timely and topical manner, we will review these advances and highlight future directions of research.
Identifiants
pubmed: 31954497
pii: S0168-8278(19)30611-7
doi: 10.1016/j.jhep.2019.10.009
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Immune Checkpoint Inhibitors
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
353-363Informations de copyright
Copyright © 2019 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.